Probiotics are becoming increasingly popular, but is there any substantial evidence supporting the efficacy of probiotics for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD)? Are there any potential risks to IBS and IBD patients using probiotic therapy? Which probiotic strains might be most beneficial, and what dosage is optimal? Dr. Charles Bernstein, director of the University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre, explores these and other questions, and suggests physicians might want to be cautious when considering probiotic therapy for their patients. Hosted by Dr. Mark DeLegge.